Zimbabwe has declined a substantial US health deal worth 367 million US dollars (272 million pounds) spanning five years over Washington's demand for sensitive information.
This move became public after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
A government spokesperson has since stated that the US was seeking genetic material for research and commercial gain while was not willing to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for further dialogue to find a agreement suitable to both sides so the country's critical HIV programme can continue.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a court halted a similar deal with the US after legal challenges were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance openness and accountability.
Based on statements, 16 nations in Africa have so far signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Agreement
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Put simply, our nation would supply the basic resources for scientific discovery without any assurance that the end products would be available to our citizens should a future pandemic emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks already established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This framework is intended to guarantee that when a country provides its data, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how future co-operation might be structured in a manner that respects the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes were funded by foreign aid.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group commented.
The halted deal emphasises the complex debate between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.